RUNX3 and carcinoma: Data from global CRISPR/Cas9 screen identified that SMARCA5 targeting was very efficient and caused cell growth inhibition in several additional AML cell lines (OCI-AML2, OCI-AML3) and also in lymphoma and carcinoma cell lines [21].